Can Oxymetholone be effectively combined with Human Growth Hormone in a single protocol?

Yes — Oxymetholone and HGH operate through mechanistically distinct receptor systems, making them genuinely complementary rather than redundant. Oxymetholone drives androgen receptor-mediated nitrogen retention and erythropoiesis, while HGH activates the GH-receptor/IGF-1R signalling axis for protein synthesis and lipolytic regulation. Their parallel mechanisms allow simultaneous use without direct pathway interference, which is why the combination is categorised as additive-to-complementary in advanced protocol design.

What specific anabolic synergies does pairing Oxymetholone with HGH produce that neither compound achieves independently?

Oxymetholone's rapid erythropoietic effect raises oxygen-carrying capacity within the first two weeks of administration, improving substrate delivery efficiency at the cellular level. HGH simultaneously elevates IGF-1, which accelerates amino acid uptake and satellite-cell activation independently of androgen receptor occupancy. Together, the stack produces an environment of enhanced substrate delivery combined with elevated anabolic signalling — an outcome that neither compound generates through its own mechanism alone.

How should an HGH and Oxymetholone stack be sequenced given that HGH requires weeks to reach IGF-1 plateau?

HGH should be started first — serum IGF-1 assay data show plateau is typically reached between weeks eight and twelve of continuous administration. Oxymetholone is then introduced as a defined four-week block once the HGH component is producing measurable IGF-1 elevation, rather than running both simultaneously from day one. This sequencing limits total oxymetholone-related hepatic enzyme exposure while ensuring the oral androgen phase coincides with peak GH/IGF-1 anabolic drive.

Does the 25 mg tablet format offer a practical advantage when adjusting dose within an HGH stack?

Yes — the 25 mg unit allows single-tablet increments or reductions without splitting, which preserves API uniformity across each administered dose. In an HGH stack where the base anabolic stimulus is already substantial, fine-tuning the oral androgen load by 25 mg rather than 50 mg steps gives practitioners meaningfully tighter control. Nassa Labs' HPLC-verified tablet uniformity ensures each adjustment reflects an actual consistent dose change.

How many tablets does the 100-tablet pack of Nassa Labs Oxymetholone 25mg provide in practical HGH-stack planning?

At a daily dose of 50 mg (two tablets), the 100-tablet pack covers exactly fifty days — supporting a four-week primary block with a residual supply for a titration ramp or a second shorter block later in the same HGH cycle. At 25 mg per day for a conservative entry phase, the pack extends to one hundred days of supply. This flexibility makes the 100-tablet count particularly practical for long-duration HGH protocols running twelve weeks or more. (2) angle_used

Brand Quality

Nassa Labs

Oxymetholone 25mg/tab 100 Tabletten by Nassa Labs

Name: Oxymetholone 25mg/tab 100 Tablets by Nassa Labs
Brand: Nassa Labs
SKU: ORA-OXYM-NAS-015
Price: 60.00 EUR
Availability: InStock

Nassa Labs Oxymetholone delivers 25 mg of pharmaceutical-grade oxymetholone per tablet across a 100-tablet supply, purpose-formulated for practitioners who pair an oral androgen with Human Growth Hormone (HGH) in a dual-axis anabolic protocol. The 25 mg tablet denomination gives granular titration control over the oral androgen contribution when the HGH component is already driving IGF-1-mediated protein synthesis — allowing the oxymetholone load to be adjusted without overshooting the combined anabolic stimulus. Quality verification follows a dual-gate release pathway: HPLC content quantification against a certified oxymetholone reference standard, then LAL endotoxin screening — both completed before any batch leaves Nassa Labs' production facility.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Activates androgen receptor-mediated erythropoiesis alongside HGH-driven IGF-1 signalling for a dual-axis anabolic environment
25 mg tablet unit enables single-step dose increments tailored to individual HGH-stack response
100-tablet supply accommodates multiple sequential oxymetholone blocks within a long-duration HGH cycle
HPLC-verified content uniformity ensures every tablet delivers the precise 25 mg declared on the label
LAL endotoxin screening on finished tablet lots confirms microbiological safety standards are met
ICH Q1A(R2)-compliant shelf-life testing validates potency retention through the registered expiry date
Batch-coded traceability links each pack to its lot-specific analytical release documentation

Phase	dosage	Note
HGH Establishment (Weeks 1–8)	HGH only; Oxymetholone not yet introduced	Allow serum IGF-1 to approach plateau before adding the oral androgen; confirm via IGF-1 assay at week 8
Induction Block (Weeks 9–10)	25 mg Oxymetholone per day (1 tablet)	Entry ramp within the established HGH cycle; baseline ALT/AST recorded before this phase begins
Peak Block (Weeks 11–12)	50 mg Oxymetholone per day (2 tablets)	Full daily dose coincides with maximum IGF-1 signal; limit continuous exposure to four weeks total across induction and peak
Exit / Washout (Weeks 13–14)	Oxymetholone discontinued; HGH continued	ALT/AST reassessed at week 13 and week 17 (four weeks post-cessation) to isolate oral-androgen hepatic contribution from HGH metabolic effects

Key takeaways

Pair Oxymetholone with HGH to activate two distinct anabolic receptor pathways simultaneously.
Introduce Oxymetholone after HGH-driven IGF-1 levels have reached measurable elevation.
Monitor ALT, AST, and haematocrit at each four-week oxymetholone block boundary.
Choose the 25 mg tablet unit for single-increment dose adjustments within HGH stacks.
Verify each Nassa Labs batch through its HPLC lot-release certificate before use.

Oxymetholone as the Androgen Axis in an HGH-Based Protocol

Oxymetholone functions as the androgen-axis driver within an HGH-paired stack, contributing erythropoietic stimulation and nitrogen-retention signalling to a protocol where Human Growth Hormone is already activating the GH/IGF-1 anabolic pathway through a mechanistically distinct receptor system. These two axes — androgen receptor-mediated transcription and GH-receptor/IGF-1R signalling — operate in parallel without direct pathway overlap, which is why their combination is classified as additive-to-complementary rather than redundant. Oxymetholone's capacity to rapidly increase red-cell mass, assessed through haematocrit monitoring during clinical use, creates an oxygen-delivery environment that amplifies the substrate utilisation efficiency associated with elevated IGF-1 signalling.

Why the 25 mg Tablet Format Matters When Stacking with HGH

Precise dose calibration becomes more consequential in an HGH stack because the combined anabolic stimulus already elevates basal protein synthesis and cellular fluid turnover without the oral androgen adding to that load. Compared to a 50 mg tablet format, the 25 mg unit allows practitioners to increment or decrement the oxymetholone contribution by a single tablet without halving — a particularly relevant advantage during the dose-titration phase of a new HGH stack where individual response to the combined signal is still being characterised. Nassa Labs' compression process targets tablet-to-tablet API uniformity confirmed by HPLC quantification, so each 25 mg unit delivers a consistent dose rather than a nominal one.

Planning the HGH + Oxymetholone Stack: Sequencing and Duration

HGH requires a minimum of eight to twelve weeks before IGF-1 elevation stabilises at plateau, as assessed by serum IGF-1 assay under standard clinical monitoring. Oxymetholone is typically introduced in discrete four-week blocks within that longer HGH window — either as an induction phase at cycle entry or as a peak-phase intensifier — rather than running the full HGH duration concurrently, which would extend hepatic enzyme exposure unnecessarily. ALT and AST values should be measured at baseline, at the end of each oxymetholone block, and again four weeks post-cessation to separate the oral androgen's hepatic contribution from any HGH-associated glucose-metabolism shift detectable on the same panel.

Nassa Labs Quality Infrastructure for Oral Oxymetholone

Every production batch of Nassa Labs Oxymetholone 25mg/tab is cleared through a two-stage analytical release: HPLC content assay against a traceable oxymetholone reference standard, then LAL endotoxin screening on the finished tablet lot. Shelf-life stability testing follows ICH Q1A(R2) accelerated and long-term protocols, ensuring that the declared 25 mg per tablet remains within specification at the registered expiry date rather than only at the time of manufacture. Each pack carries a batch code linking the physical unit to its lot-specific release documentation — a standard that supports supply-chain verification at the distributor level.

Usage

Begin HGH administration at your planned dose and run it for a minimum of eight weeks before introducing Oxymetholone, allowing serum IGF-1 to reach a measurable plateau confirmed by blood assay.
Obtain a baseline liver panel (ALT, AST, bilirubin) and haematocrit reading immediately before adding Oxymetholone to your HGH cycle so that any subsequent changes are attributable to the oral androgen.
Start Oxymetholone at 25 mg per day (one Nassa Labs tablet) for the first two weeks as an induction dose; take the tablet at a consistent time daily, ideally with a light meal to support gastric tolerance.
Escalate to 50 mg per day (two tablets) for the peak block only if the week-ten liver panel shows ALT and AST remaining within two times the upper reference limit, and haematocrit is below 54%.
Limit total continuous Oxymetholone exposure — counting induction and peak weeks combined — to four weeks, then discontinue the oral androgen while continuing HGH as planned.
Re-test ALT, AST, and haematocrit four weeks after the final Oxymetholone tablet to confirm hepatic enzyme normalisation and separate the oral androgen's metabolic signature from any HGH-associated glucose-regulation shifts visible on the same panel.

Warnings

Contraindications: Oxymetholone is contraindicated in individuals with pre-existing hepatic impairment, elevated baseline ALT/AST, active cardiovascular disease, or haematocrit values at or above 50% before cycle entry. Concurrent use with other 17α-alkylated oral compounds adds cumulative hepatotoxic load and is not advised within an HGH-paired protocol or any other stack architecture.

Side_Effects: Reported adverse effects include rapid intracellular fluid accumulation, elevation of hepatic transaminases (ALT and AST), erythrocytosis with associated blood-viscosity increase, suppression of endogenous testosterone production, and lipid-profile disruption characterised by HDL reduction. The erythropoietic drive that makes Oxymetholone complementary to HGH also increases the haematocrit-related cardiovascular risk if not monitored.

Monitoring: ALT, AST, haematocrit, fasting lipid panel, and blood pressure should be measured at baseline, at the end of each four-week Oxymetholone block, and four weeks post-cessation. Within an HGH cycle, fasting glucose and serum IGF-1 should be tracked concurrently — HGH independently affects insulin sensitivity, and the combined protocol requires clear attribution of any abnormal glucose readings to the correct compound.

PCT: Oxymetholone produces significant suppression of the hypothalamic-pituitary-gonadal axis. If Oxymetholone is used outside a cruise-and-blast framework where endogenous recovery is the goal, a structured post-cycle therapy protocol using a SERM (e.g. tamoxifen or clomiphene) should commence within days of the final tablet. HGH itself does not directly restore HPG-axis function; PCT planning must account for the androgen suppression independently of the GH component.

Frequently asked questions

Can Oxymetholone be effectively combined with Human Growth Hormone in a single protocol?: Yes — Oxymetholone and HGH operate through mechanistically distinct receptor systems, making them genuinely complementary rather than redundant. Oxymetholone drives androgen receptor-mediated nitrogen retention and erythropoiesis, while HGH activates the GH-receptor/IGF-1R signalling axis for protein synthesis and lipolytic regulation. Their parallel mechanisms allow simultaneous use without direct pathway interference, which is why the combination is categorised as additive-to-complementary in advanced protocol design.
What specific anabolic synergies does pairing Oxymetholone with HGH produce that neither compound achieves independently?: Oxymetholone's rapid erythropoietic effect raises oxygen-carrying capacity within the first two weeks of administration, improving substrate delivery efficiency at the cellular level. HGH simultaneously elevates IGF-1, which accelerates amino acid uptake and satellite-cell activation independently of androgen receptor occupancy. Together, the stack produces an environment of enhanced substrate delivery combined with elevated anabolic signalling — an outcome that neither compound generates through its own mechanism alone.
How should an HGH and Oxymetholone stack be sequenced given that HGH requires weeks to reach IGF-1 plateau?: HGH should be started first — serum IGF-1 assay data show plateau is typically reached between weeks eight and twelve of continuous administration. Oxymetholone is then introduced as a defined four-week block once the HGH component is producing measurable IGF-1 elevation, rather than running both simultaneously from day one. This sequencing limits total oxymetholone-related hepatic enzyme exposure while ensuring the oral androgen phase coincides with peak GH/IGF-1 anabolic drive.
Does the 25 mg tablet format offer a practical advantage when adjusting dose within an HGH stack?: Yes — the 25 mg unit allows single-tablet increments or reductions without splitting, which preserves API uniformity across each administered dose. In an HGH stack where the base anabolic stimulus is already substantial, fine-tuning the oral androgen load by 25 mg rather than 50 mg steps gives practitioners meaningfully tighter control. Nassa Labs' HPLC-verified tablet uniformity ensures each adjustment reflects an actual consistent dose change.
How many tablets does the 100-tablet pack of Nassa Labs Oxymetholone 25mg provide in practical HGH-stack planning?: At a daily dose of 50 mg (two tablets), the 100-tablet pack covers exactly fifty days — supporting a four-week primary block with a residual supply for a titration ramp or a second shorter block later in the same HGH cycle. At 25 mg per day for a conservative entry phase, the pack extends to one hundred days of supply. This flexibility makes the 100-tablet count particularly practical for long-duration HGH protocols running twelve weeks or more. (2) angle_used

Manufacturer

Shelf-life stability is the quality dimension Nassa Labs has chosen to anchor its Oxymetholone 25mg/tab specification around — a deliberate emphasis given that oral tablet potency degradation is one of the most common failure modes in grey-market pharmaceutical supply chains where storage conditions between manufacturer and end user are uncontrolled. Stability data for the Oxymetholone 25mg tablet lot are generated under the ICH Q1A(R2) accelerated-stability protocol (40°C/75% relative humidity, six-month minimum) and the parallel long-term storage protocol (25°C/60% RH), with HPLC-quantified content measurements taken at defined intervals across the study timeline. The outcome of this programme is an expiry date that reflects a demonstrated potency retention profile rather than a projected one — each pack's registered shelf life maps directly to a data set, not to a standard industry assumption. Batch-code traceability connects every physical pack to the specific stability lot data associated with its production run, so the declared 25 mg per tablet remains a verifiable specification at the registered expiry date, not just at the point of manufacture.

Product details

Brand	Nassa Labs
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Oxymetholonee, Nassa Labs Anadrol
Strength	25 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-OXYM-NAS-015

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00